Key takeaways
- LL-37 has no FDA-approved label and is not authorized for any medical use.
- It is a large peptide compound with a molecular weight near 4,493 daltons.
- At least 61 studies referencing LL-37 are registered on clinicaltrials.gov.
- Sample trial records in this dataset focus on related supplementation topics rather than LL-37 administration itself.
What LL-37 is
LL-37 is the name given to a peptide compound identified by PubChem CID 16198951, with the molecular formula C205H340N60O53. It is composed of a long chain of amino acids linked into a single peptide molecule. No FDA-approved drug label exists for LL-37, meaning there is no approved indication, mechanism statement, or authorized brand name to reference at this time. It remains a subject of research rather than an approved therapeutic.
Trial footprint
Registries list 61 trials associated with LL-37 research. Records included in this dataset show a mix of statuses and designs, though several examples center on related supplementation research rather than direct LL-37 administration. One withdrawn study examined vitamin D in active tuberculosis. Another, completed study looked at fermented milk and its effect on winter infectious disease occurrence, and a separate completed trial assessed vitamin D supplementation and aerobic fitness in athletes. These examples illustrate the breadth of the surrounding research landscape captured under LL-37 related searches, rather than a single defined program.